Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Citi
Colorcon
Queensland Health
Covington
Chubb
AstraZeneca
QuintilesIMS
Farmers Insurance
McKinsey

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,168,616

« Back to Dashboard

Which drugs does patent 8,168,616 protect, and when does it expire?

Patent 8,168,616 protects VALTURNA and is included in one NDA.

This patent has seventy-six patent family members in thirty-one countries.
Summary for Patent: 8,168,616
Title:Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof.
Inventor(s): Hewitt; William (Pottstown, PA), Vasella; Daniel Lucius (Basel, CH), Webb; Randy Lee (Flemington, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:10/416,039
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,168,616

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis VALTURNA aliskiren hemifumarate; valsartan TABLET;ORAL 022217-001 Sep 16, 2009 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis VALTURNA aliskiren hemifumarate; valsartan TABLET;ORAL 022217-002 Sep 16, 2009 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,168,616

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0028151.9Nov 17, 2000
PCT Information
PCT FiledNovember 15, 2000PCT Application Number:PCT/EP01/13241
PCT Publication Date:May 23, 2002PCT Publication Number: WO02/40007

Non-Orange Book US Patents Family Members for Patent 8,168,616

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,618,174 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases ➤ Subscribe
9,023,893 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases ➤ Subscribe
9,023,894 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,168,616

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 60117295 ➤ Subscribe
Germany 60134349 ➤ Subscribe
Germany 122009000021 ➤ Subscribe
Denmark 1341533 ➤ Subscribe
Denmark 1602370 ➤ Subscribe
Denmark 1915993 ➤ Subscribe
Ecuador SP034603 ➤ Subscribe
European Patent Office 1341533 ➤ Subscribe
European Patent Office 1602370 ➤ Subscribe 91563 Luxembourg ➤ Subscribe
European Patent Office 1602370 ➤ Subscribe CA 2009 00010 Denmark ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
Cantor Fitzgerald
QuintilesIMS
Novartis
Cipla
Healthtrust
Medtronic
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot